Intralipid
Intralipid has been studied in 3 papers since 2019: 1 trial and 1 observational study in people, 1 in animals; 1 in the past year. The newest paper, Nov 4, 2026: “Prospective Proteomic Associations with Incident Type 2 Diabetes and Responses to Metabolic Stress in Women with and Without Polyendocrine Metabolic Ovarian Syndrome”.
1 new paper in 30 daysSee all 8 papers on intralipid
At a glance
The findings reach people, from one lab or study. 1 lab in 3 countries; 4 trials, none about aging.
“Relative to saline, Intralipid lowered L1CAM, CHL1 and KIT at 180 min”
None of its findings points the other way.
- 1 lab in 3 countries
- 4 trials, none about aging
- Funders: Hamad Medical Corporation and 3 more
- 1 of 3 findings with company ties
- Human trial1
- Humans1
- Animals1
Studies in people
1 study gave intralipid to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases MOTS-cto 232 ± 124% of basal in control (P < 0.01) and to 349 ± 206% of basal in PCOS (P < 0.001) | Trial5 hours | WomenIn controls and PCOS subjects | Clinical endocrinology, May 15, 2019 |
What did studies of intralipid find?
3Studies of intralipid measured 3 outcomes: adiponectin, L1CAM and MOTS-c.
Adiponectin
no changein humans1
1 study
Adiponectin
no changein humans1
Intralipid showed no clear effect on adiponectin in humans (Relative to saline, in women with and without PMOS).
“no lipid-specific change in ADIPOQ was detected”
Human trialRelative to saline, in women with and without PMOSIntralipid infusion5 hfemales
International journal of molecular sciences
L1CAM
downin humans1
1 study
L1CAM
downin humans1
Intralipid decreases L1CAM in humans (Relative to saline, in women with and without PMOS) (−0.33 log2 units difference in change from baseline; FDR-adjusted p ≤ 0.029).
“Relative to saline, Intralipid lowered L1CAM, CHL1 and KIT at 180 min”
Human trialRelative to saline, in women with and without PMOSIntralipid infusion180 minfemales
International journal of molecular sciences
MOTS-c
upin humans1
1 study
MOTS-c
upin humans1
Intralipid increases MOTS-c in controls and PCOS subjects (to 232 ± 124% of basal in control (P < 0.01) and to 349 ± 206% of basal in PCOS (P < 0.001)).
“Intralipid significantly increased plasma MOTS-c both in controls and PCOS subjects”
Human trialin controls and PCOS subjects5 hours
Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects
Clinical endocrinology
Trial sponsors
Company1 trialPhase 3279 people
1 trialPhase 2120 people
University of North Carolina, Chapel Hill
1 trialPhase 1/240 people
University of Kansas Medical Center
1 trialEarly phase 146 people